A Versatile Safeguard for Chimeric Antigen Receptor T-Cell Immunotherapies.

ABSTRACT: CAR T-cell therapies hold great promise for treating a range of malignancies but are however challenged by the complexity of their production and by the adverse events related to their activity. Here we report the development of the CubiCAR, a tri-functional CAR architecture that enables CAR T-cell detection, purification and on-demand depletion by the FDA-approved antibody Rituximab. This novel architecture has the potential to streamline the manufacturing of CAR T-cells, allow their tracking and improve their overall safety.

SUBMITTER: Valton J 

PROVIDER: S-EPMC5997667 | biostudies-literature | 2018 Jun

REPOSITORIES: biostudies-literature